CTI BioPharma to Report Fourth Quarter and Full Year 2017 Financial Results on March 7, 2018
Get Alerts CTIC Hot Sheet
Join SI Premium – FREE
SEATTLE, Feb. 28, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its fourth quarter and full year 2017 financial results on Wednesday, March 7, 2018, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows:
Wednesday, March 7, 20181:30 p.m. PT/4:30 p.m. ET/10:30 p.m. CET1-800-289-0517 (domestic) +1 323-994-2084 (international)
To access the live audio webcast or the subsequent archived recording, visit CTI BioPharma's website, www.ctibiopharma.com. Webcast and telephone replays of the conference call will be available approximately two hours after completion of the call. Callers can access the replay by dialing 1-888-203-1112 (domestic) or +1 719-457-0820 (international). The access code for the replay is 2516357. The telephone replay will be available until Wednesday, March 14, 2018.
About CTI BioPharma
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. For additional information and to sign up for email alerts and get RSS feeds, please visit www.ctibiopharma.com.
CTI BioPharma Investor Contacts:Tricia Truehart+1 646 378 2953[email protected]
View original content with multimedia:http://www.prnewswire.com/news-releases/cti-biopharma-to-report-fourth-quarter-and-full-year-2017-financial-results-on-march-7-2018-300605650.html
SOURCE CTI BioPharma Corp.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Core Laboratories (CLB) Misses Q1 EPS by 13c
- Universal Health Realty (UHT) Reports Q1 EPS of $0.38
- ChampionX (CHX) Tops Q1 EPS by 8c
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!